- P-ISSN 1225-0163
- E-ISSN 2288-8985
현재 상업적으로 널리 사용 되여 지고 있는 항암제인 hydroxy urea, 6-mercaptopurine monohydrate, cytosine arabinoside, cyclophosphamide monohydrate 그리고 uracil를 3-(triethoxysilyl) propyl isocyanate 와 반응시켜 항암제가 붙어있는 3-(triethoxysilyl)propyl amide (compound I)을 합성한후 물과 가수분해 반응시켜 항암제가 결합된 silica 나노입자(10 nm~micronparticles)를 만들 수있었다. Silyl isocyanate 유도체들은 물과 반응하여 유기물질-silica 나노입자가 포함된
Commercially widely used antitumor agents such as hydroxy urea, 6-mercaptopurine monohydrate,cytosine arabinoside, cyclophosphamide monohydrate and uracil were reacted with 3-(triethoxysilyl)propyl isocyanate and the product hydrolyzed to give silica nanoparticles bound antitumor agents ranging from 10 nm to micron-sized aggregates. The silyl isocyanate derivative was also reacted neat with water to give hybrid organicsilica nanoparticles containing -CH2-CH2-CH2-NH-COOH or the corresponding decarboxylated propylamine groups depending on solvent and temperature employed. In vitro tests these functionalized silica nanoparticles were effective in the treatment of malignant tumor cells but had little or no effect on normal cells. Malignant human lung, ovarian, melanoma, CNS(Central nervous system) and colon tumor cells were used in this research. The use of silica as a carrier medium in the present research serves as a model material due to its ready functionalization via silation. The proof of concept established by the results suggests that the technique may be applied to other, more biocompatible carrier nanoparticles.